糖基化终末产物及相关药物研究进展  

Advanced glycosylation end products and related drug development

作　　者：杨秀颖[1] 杜冠华[1] 

机构地区：[1]中国协和医科大学中国医学科学院药物研究所,北京100050

出　　处：《中国药理学通报》2011年第9期1185-1188,共4页Chinese Pharmacological Bulletin

基　　金：中国科技部-魁北克合作项目(No2008DFA31710);科技部十一五"重大新药创制"科技重大专项(No2009ZX09102-123)

摘　　要：糖基化终末产物(AGEs)是蛋白质和脂类经非酶糖基化后生成的含多种结构分子的混合物,阻断AGEs的致病途径有望成为改善糖尿病慢性并发症,缓解衰老,治疗老年痴呆等的新途径。该文主要综述了体内AGEs的来源,病理生理学机制,及AGEs生成抑制剂,断裂剂及AGEs受体阻断剂的研究进展。Glycosylation end products （AGEs） are a mixture containing various structural compounds, which are products of proteins and lipids through non-enzymatic glycosylation. Bloc- king the pathogenesis of AGEs is expected to be an effective new way to improve the chronic complications of diabetes, to treat Alzheimer＇ s disease, and to ease aging. This article reviews the major source of AGEs in vivo, pathophysiological mechanisms,and the drug development of AGE-inhibitors, AGE-breakers and receptor antagonist agents of progress.

关 键 词：晚期糖基化终末产物 药物治疗 AGEs断裂剂 AGEs生成抑制剂 AGEs受体 糖尿病慢性并发症 老年痴呆 

分 类 号：R5[医药卫生—内科学] R392[医药卫生—临床医学]